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 2 
SUMMARY 3 
Background:  4 
Epistaxis is a very common ENT event. Apart from the effectiveness of the different 5 
treatment options, the discomfort and the financial burden are of great importance. It 6 
has been the aim of this study to obtain data regarding the discomfort/pain of the 7 
epistaxis treatments and to calculate the financial burden.  8 
Methodology/Principal: 9 
During the Period between 04/2010 and 07/2011 epistaxis patients at our hospital 10 
had the opportunity to rate the discomfort/pain they experienced during their 11 
treatment on a 0-10 VAS scale. The costs of epistaxis treatments were calculated in an 12 
extended cohort. 13 
Results: 84 VAS scores in 61 patients were acquired and the costs of treatment were 14 
calculated in 96 patients. The lowest VAS scores were found in chemical and electric 15 
coagulation with 1.5 and 2.0 respectively, followed by surgery (3.0), Rapid Rhino® 16 
packing (6.0) and balloon pack (7.5). The costs of treatments depended on whether 17 
the treatment was in an out- or inpatient setting. Surgery was not significantly more 18 
expensive than packing methods in the inpatient setting.  19 
Conclusions: Anterior epistaxis could be managed by local coagulation with an 20 
acceptable impact/cost ratio. At our institution, surgery was the most cost effective 21 
and the least troublesome procedure in posterior bleedings, preceded by Rapid 22 
Rhino® packing if required. 23 
 24 
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 27 
INTRODUCTION 28 
Epistaxis is a common event within the general population. It has been stated that up 29 
to 60% of the general population experiences at least once an episode of epistaxis, and 30 
6% of people with epistaxis require medical attention[1]. Due to its mainly self-31 
limiting course, it is often considered a minor medical event and yet it represents the 32 
most frequent rhinologic emergency [2]. Epistaxis is commonly divided into anterior 33 
and posterior bleedings depending on whether the source is visible upon anterior 34 
rhinoscopy. Several treatment options are available, depending upon the location of 35 
the bleeding source. Although the anatomy of each nose, the cause of epistaxis and 36 
the coexisting medical conditions can widely vary, there have been efforts to establish 37 
therapeutic algorithms and attempts to standardise epistaxis treatment at many 38 
institutions. There is only scarce literature available that compares the pain that 39 
different treatment options cause [3-7]. 40 
As with many other acute and chronic diseases, pain plays a major role in profiling 41 
the compliance of a patient and thus affecting improvement of the condition of the 42 
patient. Patients who are satisfied with their improvement are more compliant with 43 
treatment recommendations [8]. 44 
Administrative and overall health care costs show a consistent increase over the years 45 
[9] and as competition in the health care sector increases, the pressure on hospitals to 46 
reduce overall costs also increases [10]. Cost effectiveness in health care could also 47 
protect from phenomena like medical bankruptcy [11].  48 
Knowing the pain and cost of epistaxis treatment and matching them with existing 49 
data about the efficacy of each treatment we may be able to suggest to our department 50 
an epistaxis treatment model that is effective, less painful and economical [12]. 51 
 52 
 53 
MATERIALS AND METHODS 54 
 55 
Study 56 
The study was conducted prospectively in accordance with the latest version of the 57 
Helsinki declarations. The protocol was approved by the local ethics committee and 58 
review board. 59 
Treatment 60 
Our hospital is a tertiary referral centre dealing with almost 600 epistaxis’ patients 61 
annually. Each patient referred to our hospital with epistaxis was firstly examined in 62 
our ambulatory care unit. The treatment each patient received was in accordance to 63 
the treatment algorithm previously published [12]. This involves an initial treatment 64 
of less invasive options which can be expanded depending on efficacy. If the 65 
conservative treatments fail, patients are kept in hospital and surgical therapy is 66 
considered.  67 
Prior to packing and cautery, we anaesthetize the nose using oxybuprocaine spray or 68 
cotton pledgets soaked in oxybuprocaine. All patients received the same local 69 
anesthesia. For the treatment of anterior epistaxis electric or chemical cautery was the 70 
treatment of choice and very seldom was a pack used. For posterior epistaxis, an 71 
inflatable Rapid Rhino ® packing was used (7.5 cm anterior-posterior, ENT Arthrocare 72 
Europe, Stockholm, Sweden). In cases where bleeding cannot be controlled by the 73 
above mentioned method, a Foley catheter is used and is inserted through the nose 74 
until the epipharynx is reached, where it is then inflated and the nasal cavity is packed 75 
with fatty-gauze. Patients with Rapid Rhino® packing were treated either in an in- or 76 
outpatient setting. Patients with serious coexisting medical conditions, who were 77 
cardiopulmonary instable and had no good bleeding control by the pack or patients 78 
that received Foley catheter packing were treated in an inpatient setting. If this 79 
measure is not able to control bleeding a transnasal sphenopalatine artery closure is 80 
performed with diathermy and/or external ligation of the ethmoidal arteries under 81 
general anaesthesia [13]. At the end of each treatment, patients were asked to provide 82 
information about the levels of discomfort they experienced, with regards to the 83 
procedure that they had undergone.  84 
 85 
Patients 86 
Patients who were treated for epistaxis, either as outpatients or inpatients, were 87 
included, in the period between 04/2010 and 07/2011. Bleedings secondary to trauma 88 
or caused by hereditary haemorrhagic telangiectasia (M. Osler) were excluded.  89 
The following information was collected for each patient: age, sex, type of bleeding 90 
(i.e. anterior/posterior), type of treatment and visual analogue scale score for the 91 
evaluation of pain (VAS score). Costs were calculated for each treatment or treatment 92 
combination. 93 
 94 
Discomfort/ Pain 95 
A VAS questionnaire was handed out to all patients, who were treated for epistaxis.  96 
84 VAS scores in 61 patients were acquired. The patients were asked to record the 97 
discomfort experienced on a 10 cm - 11 point VAS scale (0: no pain, 10: most severe 98 
pain imaginable) for each treatment they received. If the patient underwent more than 99 
one treatment, each event was analysed separately. The evaluation form was handed 100 
out to the outpatients after the end of each treatment. With regards to patients who 101 
received packing, the levels of discomfort during insertion, remaining or removal of 102 
the device were not distinguished.  103 
Costs 104 
Costs of treatment were calculated in 96 patients. For all patients that provided VAS 105 
data, costs were calculated in accordance to the cost calculating system used in our 106 
institution. Because of the small number of treatments in some subgroups, we 107 
additionally calculated the treatment costs of a number of patients from our previous 108 
study to increase case load for the different treatments [12]. 109 
For the outpatients, the costs of epistaxis treatment were calculated based on the 110 
actual time, type of treatment and material used. This includes physical examination, 111 
the use of an electrocautery device and potential further visits i.e. for the removal of 112 
packing. Costs of all packing material were also included. Generally, patients without 113 
packing did not undergo any further visits. Patients with packing had a follow up visit 114 
for the removal of the packing and endoscopy of the nose.  115 
For inpatients, the costs were calculated on the basis of a fixed rate plus a daily 116 
charge, depending on the length of the stay. In this formula all medical 117 
accomplishments and services are included. No additional costs were charged for 118 
separate medical investigations/treatments or surgery. Follow up costs for inpatients 119 
were included, as for the outpatients, in the overall costs. 120 
 121 
 122 
Statistics  123 
Two primary endpoints were defined as the total costs of each treatment and 124 
pain/discomfort score experienced by the patient. Median values and 95% confidence 125 
intervals are provided for both the cost and VAS analyses. Comparison between 126 
treatment groups was accomplished by Mann-Whitney testing. Comparison between 127 
two VAS ratings for the same patient were analysed by the Wilcoxon matched-pairs 128 
signed rank test. The significance level alpha was set to 0.05. 129 
 130 
 131 
RESULTS 132 
The costs of treatment were calculated for the cases of 96 patients and the results can 133 
be found in Table I. 134 
A significant difference resulted in the costs between electric cautery, chemical 135 
coagulation and Rapid Rhino® on the one hand and all other treatment combinations 136 
on the other hand as it can be viewed in Figure I. Bipolar coagulation along with 137 
chemical coagulation and Rapid Rhino® packing showed the lowest costs whereas 138 
there is a wide spread of costs for the latter depending on the use in an out- or 139 
inpatient setting.  140 
All therapy options used in the inpatient setting showed much higher costs with a 141 
smaller spread. The costs for these therapies depended on the duration of 142 
hospitalisation.   143 
84 VAS scores from 61 patients were acquired. The male to female ratio was 5:3 with 144 
a median age of 72 years (range 18 to 89), while 45 patients had anterior whereas 16 145 
were found to have posterior epistaxis. The provided VAS scores are shown in Table 146 
II. There was no significant difference in the VAS scores (p=0.7) between the 147 
treatment options that were used for anteriorly located bleeding sources.  148 
Among treatment options for posterior located bleeding sources, there was a wide 149 
spread of VAS scores, with a statistically significant difference between Rapid 150 
Rhino® packing and surgery (p=0.03) and between the balloon packing and surgery 151 
(p=0.02). 152 
From those patients who required both packing and surgery, a separate rating was 153 
obtained following both treatments resulting in a time-dependent paired analysis 154 
shown in Figure III. A significantly lower discomfort value is presented in the direct 155 
comparison (p=0.02) 156 
 157 
 158 
DISCUSSION 159 
The ideal treatment for epistaxis should have three characteristics:  160 
Low-discomfort – Cost effectiveness & Low level of recurrences.  161 
The results indicate the differences in discomfort and pain between the various 162 
treatment groups. Surgery not only is less troublesome to the patient, it is also does 163 
not increase the costs of treatment. 164 
Limitations of the study 165 
While using a prospective approach, we believe that the relatively low caseload poses 166 
potential limitations in the study of treatment costs. To overcome this source of bias 167 
and to increase the validity of our cost analysis, we additionally calculated the costs of 168 
a number of treatments from our previously published retrospective study.  169 
Anterior Epistaxis 170 
According to the results of this study it can be stated that anterior epistaxis can be 171 
treated with either electric or chemical coagulation causing no significant differences 172 
in discomfort and with similar economic burden. 173 
It is known from previous investigations that chemical coagulation is more prone to 174 
failure [12]. From this point of view we conclude that it would be better to treat an 175 
anterior epistaxis with electrocautery, if possible, as all treatment failures lead to 176 
increased costs and repetitive discomfort.  177 
Posterior Epistaxis 178 
Amongst the treatment options available for posterior epistaxis, there are significant 179 
differences in the VAS scores. The lowest median VAS score was caused by surgery, 180 
followed by Rapid Rhino and balloon packing. It has been shown that the majority of 181 
patients with nasal packing can be safely managed in an outpatient setting [14]. In a 182 
previous study, discomfort upon insertion or removal of Rapid Rhino or Merocel 183 
was assessed and a significant difference, with Rapid Rhino causing less discomfort 184 
on insertion or removal, has been shown [5]. There are also a number of studies 185 
showing that the discomfort caused by Rapid Rhino is less than for other nasal 186 
packing methods not used in our study [4-7]. There is no doubt that a skilled surgeon 187 
is required in order to perform sphenopalatina artery closure. And yet, in many 188 
hospitals around the world efforts are made to treat patients with posterior bleeding 189 
primarily with surgery instead of conservative treatment [15,16]. Complications seen 190 
by the use of packing further support our belief that surgical treatment is better in 191 
managing posterior epistaxis. 192 
Regarding the economic burden that treatment options for posterior epistaxis cause, 193 
there is no significant difference between Rapid Rhino®, surgery and the balloon 194 
packing. A wide range of costs within the Rapid Rhino® treated group and a large 195 
difference between anterior and posterior treatments have been recorded. This fact is 196 
caused by the different requirements to hospitalise a patient.  While Rapid Rhino can 197 
be used safely in an outpatient setting as long as the bleeding is well controlled and 198 
the patient’s general condition allows the discharge, other treatments might require an 199 
in-hospital stay. As shown in our previous study, surgery has significantly fewer 200 
failures than packing [12]. In a review of transnasal sphenopalatine artery occlusions, 201 
either through ligation or diathermy, the overall success rate to control bleeding 202 
ranged from 92% to 100% with a mean of 98%. The literature suggests higher success 203 
rates if the sphenopalatine artery ligation is performed simultaneously with anterior 204 
ethmoidal artery ligation [16]. 205 
The major parameter that plays a role in cost calculation is the duration of the 206 
hospitalisation and this has been shown to be shorter for surgery than for nasal 207 
packing [15]. 208 
For posterior epistaxis, the costs, when comparing surgery with the other treatment 209 
options are not different. According to our cost analysis surgical treatment is not as 210 
expensive as assumed; this is in concordance with other studies [12,15,17]. 211 
Former studies stated that nasal packing has significantly lower hospital charges than 212 
surgery or intraarterial embolisation and patients who did not come to operation had 213 
fewer complications, a shorter hospital stay, and lower costs [18,19]. One limitation 214 
of our study has been the use of the local cost calculating system. Although other 215 
health care systems could come to other calculations, our results are fully in 216 
concordance with current literature that showed lower costs and better success of 217 
surgery when used as first line treatment in posterior epistaxis [15]. Two studies that 218 
were performed in 2004 and 2006 have shown that there are highly significant 219 
differences between surgery and packing not only regarding the efficacy but also the 220 
duration of hospital stay and the cost reduction [20,21] 221 
Intraarterial embolization has not been included in our treatment options due to the 222 
limited number of interventions in Zurich during the study period. A recent study 223 
about arterial embolization in the management of posterior epistaxis has shown ability 224 
to control bleeding in acute setting of 88% comparable with older reports but arterial 225 
embolization requires a well-organised setting and skilled interventional radiologists. 226 
The risks of these procedures, like cerebrovascular accidents although small should be 227 
taken into account [22]. Miller and Stevens described that there was no economic 228 
advantage for angiography compared with transnasal endoscopic sphenopalatine 229 
artery ligation [23]. 230 
Combining our results while looking at the treatment failures of the different 231 
treatment-options of an antecedent study (figure IV) it can be easily concluded that 232 
balloon packing is expensive, prone to failure and causes the most discomfort to 233 
patients.  234 
 235 
 236 
CONCLUSION 237 
According to the VAS scores obtained and costs calculated within the context of 238 
recurrences, the best treatment option for posterior epistaxis appears to be a temporary 239 
packing with a Rapid Rhino® nasal pack and consecutive surgery. 240 
With this option two therapies with a relatively low VAS-discomfort score are used, 241 
the costs are similar to other combinations used in the inpatient setting and 242 
recurrences are infrequent. Local cautery seems to be the therapy of choice in anterior 243 
bleedings. Our findings further support the idea of training young otolaryngologists to 244 
become skilled endonasal surgeons in order to control nosebleeds surgically. 245 
 246 
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323 
Table 1 324 
Treatment Total No 
(n=96) 
Costs median 
[95% CI] 
Bipolar coagulation 36 185.6 [173.2, 209.6] 
Chemical coagulation  6 203.0 [159.8, 257.6] 
Rapid Rhino® Packing 17 335.6 [834.2, 5653] 
Rapid Rhino® Packing 
+ Surgery 
10 10309 [9872, 11823] 
 
Rapid Rhino® Packing 
+ Balloon Packing 
5 10160 [9123, 11197] 
 
Rapid Rhino® Packing 
+ Balloon Packing + 
Surgery 
5 10160 [8463, 14806] 
 
Balloon Packing 5 10995 [9479, 11843] 
Balloon Packing + 
Surgery 
6 10192 [8680, 12517] 
 
Surgery 6 10269 [9407, 10986] 
 325 
Median costs in Swiss Francs are provided along with upper and lower confidence 326 
intervals and number of treatments 327 
 328 
329 
Table 2 330 
Treatment total No 
(n=) 
Median VAS score  
[95% CI] 
Chemical coagulation 14 1.5 [1.45, 3.98] 
Bipolar coagulation 40 2.0 [2.26, 3.78] 
Rapid Rhino® Packing 15 6.0 [4.18, 7.16] 
Surgery 11 3.0 [1.8, 4.93] 
Balloon Packing 4 7.5 [3.71, 11.29] 
 
 331 
Median VAS scores are provided along with upper and lower confidence intervals 332 
and number of treatments 333 
334 
Figure 1 335 
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 336 
Costs in Swiss Francs (CHF) for each treatment and combination. Significant 337 
differences indicated by * where p<0.05 and ** p<0.01.338 
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Visual analogue scale values from pain/discomoft ratings according to the different 341 
treatment forms. Significant differences are indicated (* < 0.05, ** < 0.01) 342 
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Patients who received both treatments (packing and surgery) and who rated both 346 
treatments showed significantly less discomofort by the surgical treatment. Results 347 
from Wilcoxon matched-pairs rank test. n=8 348 
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Figure 4 351 
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Treatment failures from a previously published large cohort study ([12]). * indicating 353 
significant differences. 354 
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